Details

Autor(en) / Beteiligte

• Powers, Scott W
• Coffey, Christopher S
• Chamberlin, Leigh A
• Ecklund, Dixie J
• Klingner, Elizabeth A
• Yankey, Jon W
• Korbee, Leslie L
• Porter, Linda L
• Hershey, Andrew D

Titel

Trial of Amitriptyline, Topiramate, and Placebo for Pediatric Migraine

Ist Teil von

• The New England journal of medicine, 2017-01, Vol.376 (2), p.115-124

Ort / Verlag

United States: Massachusetts Medical Society

Erscheinungsjahr

2017

Quelle

MEDLINE

Beschreibungen/Notizen

• In childhood and adolescent migraine, amitriptyline and topiramate were no better than placebo and not significantly different from each other in achieving a 50% or greater reduction in days with headache. The trial was stopped early for futility. More than 6 million children and adolescents in the United States have migraines. 1 – 3 The majority continue to have headaches into adulthood, taking a toll on the U.S. economy of approximately $36 billion and resulting in substantial effects on quality of life. 4 – 7 Pediatric clinical practice guidelines for migraine treatment are consensus based rather than evidence based, 8 , 9 with no Food and Drug Administration (FDA)–approved migraine prevention medication for children younger than 12 years of age. The Childhood and Adolescent Migraine Prevention (CHAMP) trial tested the effects of amitriptyline and topiramate in comparison with each other and with placebo in . . .